Daiichi Sankyo announced that ENHERTU (trastuzumab deruxtecan) has been approved in Japan
Daiichi Sankyo announced that ENHERTU® (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations that has progressed after chemotherapy.